Cannabidiol para la epilepsia resistente a fármacos en Argentina: evaluación de tecnología sanitaria. Rev Argent Salud Püblica 2022; 14: e80. / Cannabidiol for drug-resistant epilepsy in Argentina: health technology assessment. Rev Argent Salud Pública. 2022; 14: e80.
Med. infant
;
29(3): 261-264, Septiembre 2022.
Article
in Spanish
| LILACS, UNISALUD, BINACIS
| ID: biblio-1400796
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Technology Assessment, Biomedical
/
Drug Price
/
Cannabidiol
/
Pharmaceutical Preparations
/
Epilepsy
Limits:
Humans
Country/Region as subject:
South America
/
Argentina
Language:
Spanish
Journal:
Med. infant
Year:
2022
Type:
Article
Institution/Affiliation country:
Hospital de Pediatría Prof. Dr. Juan P. Garrahan/AR
Similar
MEDLINE
...
LILACS
LIS